<DOC>
	<DOC>NCT00282945</DOC>
	<brief_summary>The purpose of this study is to determine whether markers of b-cell function can predict changes in B-cell function over time in patients with type 2 diabetes mellitus (T2DM) randomized to treatment with metformin or rosiglitazone.</brief_summary>
	<brief_title>Beta Cell Function Tests Over Time In Patients With T2dm Randomized To Metformin Or Rosiglitazone</brief_title>
	<detailed_description>The study terminated on 17-Jul-07 due to concerns about long-term cardiovascular safety of Avandia and slow patient enrollment. There were no specific safety issues raised within the trial.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Male or female with type diabetes mellitus (diagnosed via ADA criteria), newly diagnosed or treatmentnaive (other than diet and exercise) and HbA1c range of 7 to 9%. 4570 years of age. Evidence or history of clinically significant hematological, renal, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (excluding untreated, asymptomatic, seasonal allergies).</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2008</verification_date>
</DOC>